S. T. Aaronson, P. Sears, F. Ruvuna, M. Bunker, C. R. Conway et al., A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality, Am. J. Psychiatry, vol.174, pp.640-648, 2017.

G. Abraham, R. Milev, and J. Stuart-lawson, T3 augmentation of SSRI resistant depression, J. Affect. Disord, vol.91, pp.211-215, 2006.

O. Agid and B. Lerer, Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation, Int. J. Neuropsychopharmacol, vol.6, 2003.

A. Shirawi, M. I. Kennedy, S. H. Ho, K. T. Byrne, R. Downar et al., Oral ketamine in treatment-resistant depression, J. Clin. Psychopharmacol, vol.37, pp.464-467, 2017.

K. B. Angstman, A. Marcelin, C. A. Gonzalez, T. K. Kaufman, J. A. Maxson et al., The impact of posttraumatic stress disorder on the 6-Month outcomes in collaborative care management for depression, J. Prim. Care Community Health, vol.7, pp.159-164, 2016.

B. A. Arnow, C. Blasey, L. M. Williams, D. M. Palmer, W. Rekshan et al., Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial, Am. J. Psychiatry, vol.172, pp.743-750, 2015.

R. Aronson, H. Offman, R. Joffe, and C. Naylor, Triiodothyronine augmentation in the treatment of refractory depression, Arch. Gen. Psychiatry, vol.53, 1996.

L. Baer and . Blais, Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health, LLC), 2010.

M. Bajbouj, A. Merkl, T. E. Schlaepfer, C. Frick, A. Zobel et al., Two-year outcome of vagus nerve stimulation in treatment-resistant depression, J. Clin. Psychopharmacol, vol.30, pp.273-281, 2010.

D. S. Baldwin, A. K. Huusom, and E. Maehlum, Escitalopram and paroxetine in the treatment of generalised anxiety disorder, Br. J. Psychiatry, vol.189, pp.264-272, 2006.

M. Balestri, R. Calati, D. Souery, A. Kautzky, S. Kasper et al., Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study, J. Affect. Disord, vol.189, pp.224-232, 2016.

B. Bandelow, G. Chouinard, J. Bobes, A. Ahokas, I. Eggens et al., Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study, Int. J. Neuropsychopharmacol, vol.13, p.305, 2010.

M. Bauer, M. Adli, T. Bschor, M. Pilhatsch, A. Pfennig et al., Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants, Neuropsychobiology, vol.62, pp.36-42, 2010.

M. Bauer, N. Hefting, A. Lindsten, M. K. Josiassen, and M. Hobart, A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder, Acta Neuropsychiatr, vol.31, pp.27-35, 2019.

M. Bauer, A. Pfennig, E. Severus, P. C. Whybrow, J. Angst et al., World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders, World J. Biol. Psychiatry, vol.14, pp.334-385, 2013.

M. T. Berlim and G. Turecki, What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials, Eur. Neuropsychopharmacol, vol.17, pp.696-707, 2007.

M. T. Berlim, F. Van-den-eynde, and Z. J. Daskalakis, Clinical utility of transcranial direct current stimulation (tDCS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials, J. Psychiatr. Res, vol.47, pp.1-7, 2013.

S. M. Berry, K. Broglio, M. Bunker, A. Jayewardene, B. Olin et al., A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression, Med. Devices Evid. Res, vol.6, pp.17-35, 2013.

P. Blier, H. C. Margolese, E. A. Wilson, and M. Boucher, Switching medication products during the treatment of psychiatric illness, Int. J. Psychiatry Clin. Pract, vol.23, pp.2-13, 2019.

P. Blier, H. E. Ward, P. Tremblay, L. Laberge, C. Hébert et al., Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study, Am. J. Psychiatry, vol.167, pp.281-288, 2010.

E. Brakemeier, M. Radtke, V. Engel, J. Zimmermann, B. Tuschen-caffier et al., Overcoming treatment resistance in chronic depression: a pilot study on outcome and feasibility of the cognitive behavioral analysis system of psychotherapy as an inpatient treatment program, Psychother. Psychosom, vol.84, pp.51-56, 2015.

S. Brown, K. Rittenbach, S. Cheung, G. Mckean, F. P. Macmaster et al., Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews, Can. J. Psychiatry, vol.64, pp.380-387, 2019.

A. R. Brunoni, A. H. Moffa, F. Fregni, U. Palm, F. Padberg et al., Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data, Br. J. Psychiatry, vol.208, pp.522-531, 2016.

J. Chen, L. Zhao, Y. Liu, S. Fan, and P. Xie, Comparative efficacy and acceptability of electroconvulsive therapy versus repetitive transcranial magnetic stimulation for major depression: a systematic review and multiple-treatments meta-analysis, Behav. Brain Res, vol.320, pp.30-36, 2017.

A. Cleare, C. M. Pariante, A. H. Young, I. M. Anderson, D. Christmas et al., Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines, J. Psychopharmacol, 2015.

K. R. Connolly and M. E. Thase, If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies, Drugs, vol.71, pp.43-64, 2011.

H. J. Conradi, J. Ormel, and P. De-jonge, Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study, Psychol. Med, vol.41, pp.1165-1174, 2011.

R. H. Mcallister-williams, Journal of Affective Disorders, vol.267, pp.264-282, 2020.

C. R. Conway, M. S. George, and H. A. Sackeim, Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough, JAMA Psychiatry, vol.74, pp.9-10, 2017.

R. Cooper-kazaz and B. Lerer, Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors, Int. J. Neuropsychopharmacol, vol.11, pp.685-699, 2008.

N. A. Crossley and M. Bauer, Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials, J. Clin. Psychiatry, vol.68, pp.935-940, 2007.

J. E. Cunningham and C. M. Shapiro, Cognitive behavioural therapy for insomnia (CBT-I) to treat depression: a systematic review, J. Psychosom. Res, vol.106, pp.1-12, 2018.

C. Cusin, N. Iovieno, D. V. Iosifescu, A. A. Nierenberg, M. Fava et al., A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder, J. Clin. Psychiatry, vol.74, pp.636-641, 2013.

E. J. Daly, M. H. Trivedi, A. Janik, H. Li, Y. Zhang et al., Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial, JAMA Psychiatry, vol.8560, pp.1-11, 2019.

V. De-carlo, R. Calati, and A. Serretti, Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: a systematic review, Psychiatry Res, vol.240, pp.421-430, 2016.

K. Demyttenaere, A. -. Donneau, A. Albert, M. Ansseau, E. Constant et al., What is important in being cured from: does discordance between physicians and patients matter? (2), J. Affect. Disord, vol.174, pp.372-377, 2015.

M. J. Detke, Y. Lu, D. J. Goldstein, J. R. Hayes, and M. A. Demitrack, Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebocontrolled trial, J. Clin. Psychiatry, vol.63, pp.308-315, 2002.

A. M. Deveaugh-geiss, S. L. West, W. C. Miller, B. Sleath, B. N. Gaynes et al., The adverse effects of comorbid pain on depression outcomes in primary care patients: results from the artist trial, Pain Med, vol.11, pp.732-741, 2010.

M. Dold, L. Bartova, G. Fugger, A. Kautzky, D. Souery et al., Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD), Int. J. Neuropsychopharmacol, vol.21, pp.539-549, 2018.

Y. Domany, M. Bleich-cohen, R. Tarrasch, R. Meidan, O. Litvak-lazar et al., Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebocontrolled, proof-of-concept study, Br. J. Psychiatry, vol.214, pp.20-26, 2019.

D. Dudek, J. K. Rybakowski, M. Siwek, T. Paw?owski, D. Lojko et al., Risk factors of treatment resistance in major depression: association with bipolarity, J. Affect. Disord, vol.126, pp.268-271, 2010.

M. Fava, Diagnosis and definition of treatment-resistant depression, Biol. Psychiatry, vol.53, pp.649-659, 2003.

M. Fava, M. P. Freeman, M. Flynn, H. Judge, B. B. Hoeppner et al., Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD), Mol. Psychiatry, 2018.

M. Fava, S. M. Rappe, J. A. Pava, A. A. Nierenberg, J. E. Alpert et al., Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose, J. Clin. Psychiatry, vol.56, pp.52-55, 1995.

M. Fava, A. J. Rush, J. E. Alpert, G. K. Balasubramani, S. R. Wisniewski et al., Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report, Am. J. Psychiatry, vol.165, pp.342-351, 2008.

M. Fava, M. E. Thase, C. Debattista, K. Doghramji, S. Arora et al., Modafinil augmentation of selective serotonin reuptake inhibitor therapy in mdd partial responders with persistent fatigue and sleepiness, Ann. Clin. Psychiatry, vol.19, pp.153-159, 2007.

J. Fawcett, A. J. Rush, J. Vukelich, S. H. Diaz, L. Dunklee et al., Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression, Am. J. Psychiatry, vol.173, pp.107-111, 2016.

A. Fekadu, J. G. Donocik, and A. J. Cleare, Standardisation framework for the maudsley staging method for treatment resistance in depression, BMC Psychiatry, vol.18, 2018.

P. B. Fitzgerald, K. E. Hoy, D. Elliot, S. Mcqueen, L. E. Wambeek et al., A pilot study of the comparative efficacy of 100 Hz magnetic seizure therapy and electroconvulsive therapy in persistent depression, Depress. Anxiety, vol.35, pp.393-401, 2018.

G. Fond, A. Loundou, C. Rabu, A. Macgregor, C. Lançon et al., Ketamine administration in depressive disorders: a systematic review and meta-analysis, Psychopharmacology (Berl), vol.231, pp.3663-3676, 2014.

L. Franchini, M. Gasperini, J. Perez, E. Smeraldi, and R. Zanardi, Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, doubleblind study, J. Clin. Psychiatry, vol.59, pp.229-232, 1998.

E. I. Fried and R. M. Nesse, The impact of individual depressive symptoms on impairment of psychosocial functioning, PLoS ONE, vol.9, 2014.

G. Fugger, M. Dold, L. Bartova, A. Kautzky, D. Souery et al., Comorbid hypertension in patients with major depressive disorder -Results from a European multicenter study, Eur. Neuropsychopharmacol, vol.29, pp.777-785, 2019.

D. F. Gardner, S. G. Kornstein, and E. F. Sholar, Endocrine disorders. Psychosocial Treatment for Medical Conditions. Routledge, pp.215-244, 2004.

B. N. Gaynes, S. W. Lloyd, L. Lux, G. Gartlehner, R. A. Hansen et al., Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis, J. Clin. Psychiatry, vol.75, pp.477-489, 2014.

B. N. Gaynes, G. Asher, G. Gartlehner, V. Hoffman, J. Green et al., Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the global burden of disease study, AHRQ Technology Assessments. Agency for Healthcare Research and Quality, vol.388, issue.16, p.31460, 2015.

A. H. Glassman, C. M. O'connor, R. M. Califf, K. Swedberg, P. Schwartz et al., Sertraline treatment of major depression in patients with acute MI or unstable angina, JAMA, vol.288, pp.701-709, 2002.

G. M. Goodwin, P. M. Haddad, I. N. Ferrier, J. K. Aronson, T. Barnes et al., Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology, J. Psychopharmacol, vol.30, pp.495-553, 2016.

A. J. Goss, M. Kaser, S. G. Costafreda, B. J. Sahakian, and C. H. Fu, Modafinil augmentation therapy in unipolar and bipolar depression, J. Clin. Psychiatry, vol.74, pp.1101-1107, 2013.

H. Grunze, E. Vieta, G. M. Goodwin, C. Bowden, R. W. Licht et al., The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder, Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic, vol.19, pp.2-58, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01791676

T. Guo, Y. Xiang, L. Xiao, C. Hu, H. F. Chiu et al., Measurement-Based care versus standard care for major depression: a randomized controlled trial with blind raters, Am. J. Psychiatry, vol.172, pp.1004-1013, 2015.

, Repetitive transcranial magnetic stimulation for treatmentresistant depression: a systematic review and meta-analysis of randomized controlled trials, Ont. Health Technol. Assess. Ser, vol.16, pp.1-66, 2016.

M. T. Hegel, J. Unützer, L. Tang, P. A. Areán, W. Katon et al., Impact of comorbid panic and posttraumatic stress disorder on outcomes of collaborative care for late-life depression in primary care, Am. J. Geriatr. Psychiatry, vol.13, pp.48-58, 2005.

W. T. Heijnen, T. K. Birkenhäger, A. I. Wierdsma, and W. W. Van-den-broek, Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy, J. Clin. Psychopharmacol, vol.30, pp.616-619, 2010.

J. K. Hicks, J. R. Bishop, R. S. Gammal, K. Sangkuhl, C. A. Bousman et al., A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant pharmacotherapy, Clin. Pharmacol. Ther, 2019.

M. Hobart, A. Skuban, P. Zhang, M. K. Josiassen, N. Hefting et al., Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study, Curr. Med. Res. Opin, vol.34, pp.633-642, 2018.

R. Hoehn-saric, P. Ninan, D. W. Black, S. Stahl, J. H. Greist et al., Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders, Arch. Gen. Psychiatry, vol.57, pp.76-82, 2000.

R. H. Howland, Thyroid dysfunction in refractory depression: implications for pathophysiology and treatment, J. Clin. Psychiatry, vol.54, pp.47-54, 1993.

R. H. Howland, A. J. Rush, S. R. Wisniewski, M. H. Trivedi, D. Warden et al., Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome, Drug Alcohol Depend, vol.99, pp.248-260, 2009.

D. V. Iosifescu, A. A. Nierenberg, D. Mischoulon, R. H. Perlis, G. I. Papakostas et al., An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder, J. Clin. Psychiatry, vol.66, pp.1038-1042, 2005.

W. W. Ishak, J. Mirocha, D. James, G. Tobia, J. Vilhauer et al., Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up, Acta Psychiatr. Scand, vol.131, pp.51-60, 2015.

K. Itagaki, M. Takebayashi, C. Shibasaki, N. Kajitani, H. Abe et al., Factors associated with relapse after a response to electroconvulsive therapy in unipolar versus bipolar depression, J. Affect. Disord, vol.208, pp.113-119, 2017.

E. Jääskeläinen, T. Juola, H. Korpela, H. Lehtiniemi, M. Nietola et al., Epidemiology of psychotic depression -systematic review and meta-analysis, Psychol. Med, vol.48, pp.905-918, 2018.

A. Jelovac, E. Kolshus, and D. M. Mcloughlin, Relapse following successful electroconvulsive therapy for major depression: a meta-analysis, Neuropsychopharmacology, vol.38, pp.2467-2474, 2013.

R. T. Joffe, S. T. Sokolov, and A. J. Levitt, Lithium and triiodothyronine augmentation of antidepressants, Can. J. Psychiatry, vol.51, pp.791-793, 2006.

L. L. Judd, H. S. Akiskal, J. D. Maser, P. J. Zeller, J. Endicott et al., Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse, J. Affect. Disord, vol.50, pp.97-108, 1998.

M. Kaser, J. B. Deakin, A. Michael, C. Zapata, R. Bansal et al., Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study, Biol. Psychiatry Cogn. Neurosci. Neuroimaging, vol.2, pp.115-122, 2017.

A. Kautzky, P. Baldinger-melich, G. S. Kranz, T. Vanicek, D. Souery et al., A new prediction model for evaluating treatment-resistant depression, J. Clin. Psychiatry, vol.78, pp.215-222, 2017.

A. Kautzky, M. Dold, L. Bartova, M. Spies, T. Vanicek et al., Refining prediction in treatment-resistant depression, J. Clin. Psychiatry, vol.79, 2018.

S. Kayser, B. H. Bewernick, C. Grubert, B. L. Hadrysiewicz, N. Axmacher et al., Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression, J. Psychiatr. Res, vol.45, pp.569-576, 2011.

M. B. Keller, P. W. Lavori, J. Endicott, W. Coryell, and G. L. Klerman, Double depression": two-year follow-up, Am. J. Psychiatry, vol.140, pp.689-694, 1983.

N. Kennedy and E. S. Paykel, Residual symptoms at remission from depression: impact on long-term outcome, J. Affect. Disord, vol.80, issue.03, pp.54-59, 2004.

S. H. Kennedy, R. W. Lam, R. S. Mcintyre, S. V. Tourjman, V. Bhat et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments, Can. J. Psychiatry, vol.61, pp.540-560, 2016.

D. Kessler, A. Burns, D. Tallon, G. Lewis, S. Macneill et al., Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT, Health Technol. Assess, p.22, 2018.

. I-136,

S. Kisely, A. Li, N. Warren, and D. Siskind, A systematic review and meta-analysis of deep brain stimulation for depression, Depress. Anxiety, vol.35, pp.468-480, 2018.

J. H. Kocsis, A. J. Gelenberg, B. O. Rothbaum, D. N. Klein, M. H. Trivedi et al., Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP trial, Arch. Gen. Psychiatry, vol.66, pp.1178-1188, 2009.

S. G. Kornstein and R. K. Schneider, Clinical features of treatment-resistant depression, J. Clin. Psychiatry, vol.62, pp.18-25, 2001.

C. Kraus, B. Kadriu, R. Lanzenberger, C. A. Zarate, and S. Kasper, Prognosis and improved outcomes in major depression: a review, Transl. Psychiatry, vol.9, 2019.

K. Kronström, H. Karlsson, H. Nabi, T. Oksanen, P. Salo et al., Optimism and pessimism as predictors of work disability with a diagnosis of depression: a prospective cohort study of onset and recovery, J. Affect. Disord, vol.130, pp.294-299, 2011.

A. Kumar, M. T. Bunker, S. T. Aaronson, C. R. Conway, A. J. Rothschild et al., Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression, Neuropsychiatr. Dis. Treat, vol.15, pp.457-468, 2019.

R. Luqmani, S. Hennell, C. Estrach, D. Basher, F. Birrell et al., British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management, 2009.

, Rheumatology (Oxford), vol.48, pp.436-439

A. R. Mahableshwarkar, J. Zajecka, W. Jacobson, Y. Chen, and R. S. Keefe, A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder, Neuropsychopharmacology, vol.40, pp.2025-2037, 2015.

G. S. Malhi, P. Das, Z. Mannie, and L. Irwin, Treatment-resistant depression: problematic illness or a problem in our approach?, Br. J. Psychiatry, vol.214, pp.1-3, 2019.

G. S. Malhi and J. J. Mann, Depression. Lancet, vol.392, issue.18, pp.31948-31950, 2018.

R. H. Mcallister-williams, D. M. Christmas, A. J. Cleare, A. Currie, J. Gledhill et al., Multiple-therapy-resistant major depressive disorder: a clinically important concept, Br. J. Psychiatry, vol.212, pp.274-278, 2018.

J. P. Mccullough, D. N. Klein, M. B. Keller, C. E. Holzer, S. M. Davis et al., Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction, J. Abnorm. Psychol, vol.109, pp.419-427, 2000.

A. Mcgirr, P. A. Vöhringer, S. N. Ghaemi, R. W. Lam, and L. N. Yatham, Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials, Lancet Psychiatry, vol.3, pp.1138-1146, 2016.

D. L. Mcmakin, T. M. Olino, G. Porta, L. J. Dietz, G. Emslie et al., Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression, J. Am. Acad. Child Adolesc. Psychiatry, vol.51, pp.404-411, 2012.

D. Meron, N. Hedger, M. Garner, and D. S. Baldwin, Transcranial direct current stimulation (tDCS) in the treatment of depression: systematic review and meta-analysis of efficacy and tolerability, Neurosci. Biobehav. Rev, vol.57, pp.46-62, 2015.

R. V. Milev, P. Giacobbe, S. H. Kennedy, D. M. Blumberger, Z. J. Daskalakis et al., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. Neurostimulation treatments, Can. J. Psychiatry, vol.61, pp.561-575, 2016.

S. A. Montgomery, K. Tobias, G. L. Zornberg, S. Kasper, and A. C. Pande, Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine, J. Clin. Psychiatry, vol.67, pp.771-782, 2006.

I. D. Morres, A. Hatzigeorgiadis, A. Stathi, N. Comoutos, C. Arpin-cribbie et al., Aerobic exercise for adult patients with major depressive disorder in mental health services: a systematic review and meta-analysis, Depress. Anxiety, vol.36, pp.39-53, 2019.

J. Nelson, A. Klumparendt, P. Doebler, and T. Ehring, Childhood maltreatment and characteristics of adult depression: meta-analysis, Br. J. Psychiatry, vol.210, pp.96-104, 2017.

J. C. Nelson, Treatment of antidepressant nonresponders: augmentation or switch?, J. Clin. Psychiatry, vol.59, pp.35-41, 1998.

J. C. Nelson, P. Baumann, K. Delucchi, R. Joffe, and C. Katona, A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression, J. Affect. Disord, vol.168, pp.269-275, 2014.

J. C. Nelson and G. I. Papakostas, Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials, Am. J. Psychiatry, vol.166, pp.980-991, 2009.

A. A. Nierenberg, M. Fava, M. H. Trivedi, S. R. Wisniewski, M. E. Thase et al., A comparison of lithium and T 3 augmentation following two failed medication treatments for depression: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1519-1530, 2006.

I. Pacchiarotti, D. J. Bond, R. J. Baldessarini, W. A. Nolen, H. Grunze et al.,

K. Ha, G. Perugi, S. Kasper, J. D. Amsterdam, R. M. Hirschfeld et al., The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders, Am. J. Psychiatry, vol.170, pp.1249-1262, 2013.

C. -. Pae, A. A. Patkar, S. Jang, K. B. Portland, S. Jung et al., Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials, CNS Spectr, vol.19, pp.324-329, 2014.

G. I. Papakostas, Managing partial response or nonresponse, J. Clin. Psychiatry, vol.70, pp.16-25, 2009.

G. I. Papakostas, M. Fava, L. Baer, M. B. Swee, A. Jaeger et al., Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study, Am. J. Psychiatry, vol.172, pp.1251-1258, 2015.

G. I. Papakostas, D. Mischoulon, I. Shyu, J. E. Alpert, and M. Fava, S -Adenosyl Methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial, Am. J. Psychiatry, vol.167, pp.942-948, 2010.

G. I. Papakostas, T. J. Petersen, A. H. Farabaugh, J. L. Murakami, J. A. Pava et al., Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder, J. Clin. Psychiatry, vol.64, pp.1357-1361, 2003.

G. I. Papakostas, R. C. Shelton, J. Smith, and M. Fava, Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis, J. Clin. Psychiatry, vol.68, pp.826-831, 2007.

S. V. Parikh, L. C. Quilty, P. Ravitz, M. Rosenbluth, B. Pavlova et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments, Can. J. Psychiatry, vol.61, pp.524-539, 2016.

K. Perlman, D. Benrimoh, S. Israel, C. Rollins, E. Brown et al., A systematic metareview of predictors of antidepressant treatment outcome in major depressive disorder, J. Affect. Disord, vol.243, pp.503-515, 2019.

G. Perugi, I. Pacchiarotti, C. Mainardi, N. Verdolini, G. Menculini et al., Patterns of response to antidepressants in major depressive disorder: drug resistance or worsening of depression are associated with a bipolar diathesis, Eur. Neuropsychopharmacol, vol.29, pp.825-834, 2019.

J. L. Phillips, S. Norris, J. Talbot, M. Birmingham, T. Hatchard et al., Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial, Am. J. Psychiatry, vol.176, pp.401-409, 2019.

V. Popova, E. J. Daly, M. Trivedi, K. Cooper, R. Lane et al., Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study, Am. J. Psychiatry, vol.176, pp.428-438, 2019.

D. Rhebergen, A. T. Beekman, R. Graaf, . De, W. A. Nolen et al., The three-year naturalistic course of major depressive disorder, dysthymic disorder and double depression, J. Affect. Disord, vol.115, pp.450-459, 2009.

I. Romera, V. Perez, J. M. Menchón, H. Delgado-cohen, P. Polavieja et al., Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study, Eur. Psychiatry, vol.25, pp.58-65, 2010.

A. R. Rosa, J. Sánchez-moreno, A. Martínez-aran, M. Salamero, C. Torrent et al., Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder, Clin. Pract. Epidemiol. Ment. Heal, vol.3, 2007.

J. D. Rosenblat, A. F. Carvalho, M. Li, Y. Lee, M. Subramanieapillai et al., Oral ketamine for depression, J. Clin. Psychiatry, vol.80, 2019.

F. Rost, P. Luyten, P. Fearon, and P. Fonagy, Personality and outcome in individuals with treatment-resistant depression-Exploring differential treatment effects in the Tavistock Adult Depression Study (TADS), J. Consult. Clin. Psychol, vol.87, pp.433-445, 2019.

H. G. Ruhé, G. Van-rooijen, J. Spijker, F. P. Peeters, and A. H. Schene, Staging methods for treatment resistant depression. A systematic review, J. Affect. Disord, vol.137, pp.35-45, 2012.

A. J. Rush, S. T. Aaronson, and K. Demyttenaere, Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive, Aust. N. Z. J. Psychiatry, vol.53, pp.109-118, 2019.

A. J. Rush, L. B. Marangell, H. A. Sackeim, M. S. George, S. K. Brannan et al., Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study, Biol. Psychiatry, vol.58, pp.355-363, 2005.

A. J. Rush and M. E. Thase, Improving depression outcome by patient-centered medical management, Am. J. Psychiatry, vol.175, pp.1187-1198, 2018.

A. J. Rush, M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart et al., Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report, Am. J. Psychiatry, vol.163, pp.1905-1917, 1905.

A. J. Rush, S. R. Wisniewski, D. Warden, J. F. Luther, L. L. Davis et al., Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features, Arch. Gen. Psychiatry, vol.65, pp.870-880, 2008.

E. Salagre, B. Solé, Y. Tomioka, B. S. Fernandes, D. Hidalgo-mazzei et al., Treatment of neurocognitive symptoms in unipolar depression: a systematic review and future perspectives, J. Affect. Disord, vol.221, pp.205-221, 2017.

A. F. Schatzberg, A. J. Rush, B. A. Arnow, P. L. Banks, J. A. Blalock et al., Chronic depression, Arch. Gen. Psychiatry, vol.62, 2005.

T. E. Schlaepfer, C. Frick, A. Zobel, W. Maier, I. Heuser et al., Vagus nerve stimulation for depression: efficacy and safety in a European study, Psychol. Med, vol.38, pp.651-661, 2008.

G. Serafini, R. Howland, F. Rovedi, P. Girardi, and M. Amore, The role of ketamine in treatment-resistant depression: a systematic review, Curr. Neuropharmacol, vol.12, pp.444-461, 2014.

V. Sharma, M. Khan, and A. Smith, A closer look at treatment resistant depression: is it due to a bipolar diathesis?, J. Affect. Disord, vol.84, pp.251-257, 2005.

K. H. Sheehan and D. V. Sheehan, Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale, Int. Clin. Psychopharmacol, vol.23, pp.70-83, 2008.

P. Shiozawa, F. Fregni, I. M. Benseñor, P. A. Lotufo, M. T. Berlim et al., Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis, Int. J. Neuropsychopharmacol, vol.17, pp.1443-1452, 2014.

M. M. Sidor and G. M. Macqueen, An update on antidepressant use in bipolar depression, Curr. Psychiatry Rep, vol.14, pp.696-704, 2012.

J. B. Singh, M. Fedgchin, E. J. Daly, P. De-boer, K. Cooper et al., A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatmentresistant depression, Am. J. Psychiatry, vol.173, pp.816-826, 2016.

D. Souery, P. Oswald, I. Massat, U. Bailer, J. Bollen et al., Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study, J. Clin. Psychiatry, vol.68, pp.1062-1070, 2007.

G. I. Spielmans, M. I. Berman, E. Linardatos, N. Z. Rosenlicht, A. Perry et al., Adjunctive atypical antipsychotic treatment for major depressive disorder: a metaanalysis of depression, quality of life, and safety outcomes, PLoS Med, vol.10, 2013.

M. Takahashi, Y. Shirayama, K. Muneoka, M. Suzuki, K. Sato et al., Personality traits as risk factors for treatment-resistant depression, PLoS ONE, vol.8, 2013.

M. Takahashi, Y. Shirayama, K. Muneoka, M. Suzuki, K. Sato et al., Low openness on the revised NEO personality inventory as a risk factor for treatmentresistant depression, PLoS ONE, vol.8, 2013.

M. E. Thase, J. M. Youakim, A. Skuban, M. Hobart, C. Augustine et al., Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants, J. Clin. Psychiatry, vol.76, pp.1224-1231, 2015.

M. E. Thase, J. M. Youakim, A. Skuban, M. Hobart, P. Zhang et al., Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study, J. Clin. Psychiatry, vol.76, pp.1232-1240, 2015.

M. H. Trivedi, M. Fava, S. R. Wisniewski, M. E. Thase, F. Quitkin et al., Medication augmentation after the failure of SSRIs for depression, 2006.

. Engl, J. Med, vol.354, pp.1243-1252

C. Tunnard, L. J. Rane, S. C. Wooderson, K. Markopoulou, L. Poon et al., The impact of childhood adversity on suicidality and clinical course in treatment-resistant depression, J. Affect. Disord, vol.152, issue.154, 2014.

R. Uher, R. H. Perlis, N. Henigsberg, A. Zobel, M. Rietschel et al., Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, Psychol. Med, vol.42, pp.967-980, 2012.

E. Vieta, L. B. Sluth, and C. K. Olsen, The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram, J. Affect. Disord, vol.227, pp.803-809, 2018.

R. Warner, Recovery from schizophrenia and the recovery model, Curr. Opin. Psychiatry, vol.22, pp.374-380, 2009.

N. Wiles, A. Taylor, N. Turner, M. Barnes, J. Campbell et al., Management of treatment-resistant depression in primary care: a mixed-methods study, Br. J. Gen. Pract, vol.68, pp.673-681, 2018.

N. Wiles, L. Thomas, A. Abel, N. Ridgway, N. Turner et al., Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the Cobalt randomised controlled trial, Lancet, vol.381, pp.375-384, 2013.

, , pp.61552-61561

K. Wilhelm, Judging a book by its cover: changing "treatment resistant" to "difficult-to-treat" depression, Aust. N. Z. J. Psychiatry, vol.53, pp.101-103, 2019.

L. N. Yatham, S. H. Kennedy, S. V. Parikh, A. Schaffer, D. J. Bond et al., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder, Bipolar Disord, vol.20, pp.97-170, 2018.

C. Zhou, H. Zhang, Y. Qin, T. Tian, B. Xu et al., A systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression, Prog. Neuro-Psychopharmacology Biol. Psychiatry, vol.82, pp.224-232, 2018.

X. Zhou, G. I. Keitner, B. Qin, A. V. Ravindran, M. Bauer et al., Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis, Int. J. Neuropsychopharmacol, vol.18, pp.1-10, 2015.

M. Zimmerman, J. B. Mcglinchey, M. A. Posternak, M. Friedman, N. Attiullah et al., How should remission from depression be defined? The depressed patient's perspective, Am. J. Psychiatry, vol.163, pp.148-150, 2006.